SmallCapReview.com To Add Revolutions Medical Corporation (RMCP) To Its Portfolio
SmallCapReview.com a leading site for small cap information is adding Revolutions Medical Corporations (RMCP) to its list of stocks “On the Radar”.
RMCP products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter.
The world market for safety-engineered medical devices (SEMDs) is projected to exceed 2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term.
Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D, and automatic segmentation of images. These tools will enhance the physician’s diagnostic confidence in an industry that is growing at 10% – 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion.
RMCP Investor Highlights
With traditional syringes and phlebotomy devices, a needle contaminated with a patient’s blood remains a danger to healthcare professionals handling the needle until it is permanently disposed of in a proper biohazard containment unit. RMCP’s safety products do not present a “needlestick” hazard to health professionals after use because the contaminated needle is retracted into the barrel of the safety product and locked in place.
Recently announced that it has completed a significant redesign of its flagship Rev Vac syringe, reducing the product’s part count by nearly 30% and clearing the remaining economic hurdles to mass production and commercial launch. The Rev Vac safety syringe is already FDA approved.
The Rev Vac Safety Syringe and Phlebotomy (blood drawing) Device operate the same as a standard syringe and device. No additional training, skills, or procedures are necessary.
The Company has said that it is firmly on pace to achieve its intended Q4 ‘09 mass market launch.
RMCP has stated it will bring the Rev Vac to market at less than half the published cost of its closes competitor’s needle.
The world market for safety-engineered medical devices (SEMDs) is projected to exceed 2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term.
RMCP’s portfolio of intellectual properties continues to grow. They will soon have 4 U.S. patent applications protecting their newly acquired Breast Biopsy System. RMCO already has 4 U.S. patent applications pending on its RevColor and Rev3D software technology plus comparable European patent protection filings. The RevVac Safety Syringe has 2 U.S. patents issued plus many additional individual country filings’ protecting the safety syringe patent rights internationally.
The Company’s software technology uses various color masks to produce full-color composite images from gray-scale MRI output. The resulting color images can be quickly viewed individually or all together as a “riffle stack”.
RMCP has secured 10 million dollars in equity financing to ramp up production.
With the H1N1 (Swine) Flu of great concern to all people, the need for safety-engineered medical devices such as the FDA approved, Rev Vac Safety Syringe made by the Company could be in great demand in order to inject the H1N1 flu vaccine quickly and safely.
RMCP is committed to continually developing and distributing new products and tools to the medical industry, whether internally or through acquisitions. Its goals are to make health care safer and less expensive by reducing risks and cutting time and expenses. To learn more about RMCP visit http://www.smallcapreview.com/rmcp.htm
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has been compensated up to three thousand five hundred dollars by a third party APS for its services with regards to Revolutions Medical Corporations.
CONTACT: Daniel Minton, Managing Director, 406-862-5400, daniel@accelerize.com